PD16: Prostate Cancer: Advanced (including Drug Therapy) III

Saturday, April 29, 2023

9:30 AM – 11:30 AM CST

Location: S401C

CE: 1

Podium Session Moderator(s)

Brian Chapin, MD

MD
The University of Texas, MD. Anderson Cancer Center
Daniel Petrylak, MD

Professor of Medicine (Medical Oncology) and of Urology
Yale University
Marcelo Wroclawski, MD,MSc

Hospital Israelita Albert Einstein

Presentations:

9:30 AM – 9:40 AM CST

PD16-01: Synergistic effects of curcumin and lactoferrin to inhibit the prostatic cancer cells growth and migration ability
Podium Presenter: Michele Marchioni, PhD (he/him/his)
9:40 AM – 9:50 AM CST

PD16-02: Concurrent targeting AR/AR variants and AKR1C3 for advanced prostate cancer therapy
Podium Presenter: Allen Gao, MD, PhD – UC Davis School of Medicine
9:50 AM – 10:00 AM CST

PD16-03: Prognostic value of Prostate-specific antigen kinetics during treatment of advanced prostate cancer with Abiraterone and Enzalutamide: Multicenter Analysis
Podium Presenter: Byeong Jin Kang, MD – Pusan National University Hospital
10:00 AM – 10:10 AM CST

PD16-04: Differential Treatment Response of Prostate and Metastatic Lesions in Patients with Newly Diagnosed Metastatic Prostate Cancer
Podium Presenter: Yakup Kordan
10:10 AM – 10:20 AM CST

PD16-05: A SYSTEMATIC REVIEW TO EVALUATE PATIENT-REPORTED OUTCOMES MEASURES (PROMS) FOR METASTATIC PROSTATE CANCER ACCORDING TO THE COSMIN METHODOLOGY: A PIONEER WP2 PROJECT
Podium Presenter: Maria Monica Ratti
10:20 AM – 10:30 AM CST

PD16-06: Examining Testosterone Recovery in Androgen Deprivation Therapy for Prostate Cancer
Podium Presenter: Mark A. Preston
10:30 AM – 10:40 AM CST

PD16-07: Post-prostatectomy adjuvant androgen deprivation therapy-- patient opinions and goals of care
Podium Presenter: Max Levitt
10:40 AM – 10:50 AM CST

PD16-08: Cost-effectiveness of systemic treatment intensification in men with metastatic hormone-sensitive prostate cancer
Podium Presenter: Niranjan Sathianathen
10:50 AM – 11:00 AM CST

PD16-09: Risk Analysis of Metformin Use in Prostate Cancer Risk: A National Population-Based Study
Podium Presenter: Younghun Sim, MD
11:00 AM – 11:10 AM CST

PD16-10: Far from the truth: Real-world treatment patterns among newly diagnosed metastatic prostate cancer in the era of treatment intensification
Podium Presenter: Yu Guang Tan, Esq., MD, MBBS – Singapore General Hospital
11:10 AM – 11:20 AM CST

PD16-11: Real World Characterization of Patients Receiving Relugolix or Androgen Deprivation Therapy Injections in Combination with Oral Anti-Androgens in 2021 (The REAL ADT ORAL Study): Analysis from a US EMR Database
Podium Presenter: Jason Matthew Hafron, MD
11:20 AM – 11:30 AM CST

PD16-12: Real-World Outcomes Among Men with Nonmetastatic Castration-sensitive Biochemical Recurrence After Definitive Therapy With Short PSA Doubling Time Receiving Early Secondary Treatment
Podium Presenter: Stephen J. Freedland, MD (he/him/his)